Navigation Links
OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
Date:11/14/2012

re evaluable at the six-month follow-up. The complete response rate at six months among basal cell carcinomas was 92.8 percent and 70 percent among squamous cell carcinomas. Response rate of melanoma was not calculated since multiple tumors were treated with concomitant therapy. The treatment was well-tolerated. The most frequent treatment-related adverse events were pain, infection and insomnia; all were transient and manageable. 

NeoPulse appears well-tolerated and able to achieve local control comparable to that of surgical resection. The potential advantage of the therapy lies with the preservation of normal tissue with improved cosmesis, avoiding the need for reconstruction in difficult-to-treat sites or those with significant innervation. Together with the possible reduction in cost associated with hospitalization for procedures involving extensive reconstruction, the approach warrants further exploration as an alternative in select cases of skin cancer.

Punit Dhillon, President and CEO of OncoSec Medical, said, "These data demonstrate how NeoPulse might serve as an alternative to surgery that selectively destroys cancer cells without harming normal, healthy tissue. The results of OncoSec's skin cancer program have so far shown a positive outcome among the class of patients who would typically be subjected to disfiguring surgery. We believe that NeoPulse offers a potentially significant new treatment for a variety of skin cancers."

About the Phase IV Study

This Phase IV study was designed as an open-labeled study to measure local control and pharmacoeconomic parameters for NeoPulse in primary or recurrent squamous cell carcinoma of the skin, basal cell carcinoma as well as recurrent metastatic melanoma. Patients with primary or recurrent histologically confirmed tumors with no evidence of brain mestastases were eligible for enrollment. Safety and local control were measured. Patients received local injection of bleomycin follo
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Present at Upcoming Healthcare and Investor Conferences
2. OncoSec Granted New Patent from China
3. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
4. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
7. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
8. OncoSec Medical Issues Letter to Shareholders
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. Filtrona Porous Technologies Introduces New Medical-Grade Foams And Unique Fiber Products For Clean Environments At MEDICA / COMPAMED Trade Fair
11. Rochester Medical Reports Record Fourth Quarter and Fiscal Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... ., Aug. 22, 2014  Research presented at the ... therapy being developed by Hera Therapeutics Inc. combats three types ... of all cervical cancer. When tested in several ... HPV-18 and HPV-11 cells, according to Louise T. Chow ... the findings at the Seattle conference. ...
(Date:8/22/2014)... /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... technologies and products for advanced microarray diagnostics, today ... Service Agreement to contract with a UK-based company ... the initial phase of this agreement, SQI will ... of one of the customer,s assays, operational on ...
(Date:8/21/2014)... Ill. , Aug. 21, 2014 ... Baxter International Inc. today announced positive results from ... 855, an investigational, extended half-life recombinant factor VIII ... [Antihemophilic Factor (Recombinant)], which met its primary endpoint ... prophylaxis arm compared to the on-demand arm. ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... in combination with the most commonly used doses of ... patients with mixed dyslipidemiaORLANDO, Fla., March 29 Data ... TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with rosuvastatin ... TRILIPIX 135 mg in combination with rosuvastatin calcium 5 ...
... March 29 A new analysis from the,JUPITER ... the risk of venous thromboembolism (VTE) by 43% ... with low to normal cholesterol levels and elevated,high-sensitivity ... the 58th Annual American College of Cardiology Scientific ...
Cached Medicine Technology:New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5CRESTOR(R) Reduced Risk of Blood Clots in the Veins 2CRESTOR(R) Reduced Risk of Blood Clots in the Veins 3CRESTOR(R) Reduced Risk of Blood Clots in the Veins 4
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Mi40x ... uses university-proven research to show people how they can use ... muscle in only a matter of weeks has caught the ... “Ben Pakulski is one of the most well-known bodybuilders in ... the body he has today, that in itself is a ...
(Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
(Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
(Date:8/22/2014)... A new study of self-awareness by Kessler Foundation ... may be able to improve their self-awareness through ... of print on July 2 in NeuroRehabilitation ... D. Chiaravalloti & John DeLuca: Metacognitive knowledge and ... 10.3233/NRE-141113). Self-awareness is one,s ability to recognize cognitive ...
(Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... gene (MTDH) plays a role in both cancer metastasis ... Press in the January 6th issue of the journal ... therapeutic target for high risk breast cancers. , "Most ... succumb to recurrent tumors that spread to distant vital ...
... , The Fifth International Conference on Cell Therapy ... on stem cells for non-cardiac organ injury. The session ... disease and diabetes, bone marrow cells for stroke patients, ... , Highlights from other sessions include the first human ...
... in the U.S. each year have been exposed to alcohol or ... by the National Center on Substance Abuse and Child Welfare. If ... remain in foster care longer, and chances are very low that ... study led by Joseph P. Ryan, a faculty member in the ...
... PR Newswire Staff Volunteer Time As Part ... InitiativeCLEVELAND, Jan. 5 Ronald McDonald House of ... two non-profit organizations serving the Cleveland community, were ... hours from PR Newswire,s Cleveland staff in 2008, ...
... cost Medicaid hundreds of millions of dollars annually in ... could not only improve outcomes but also save substantial ... examined records of nearly 150,000 people in six states. ... more than they think," said Robin E. Clark, PhD, ...
... OF PLASTIC SURGEONSARLINGTON HEIGHTS, Ill., Jan. 5 The ... Plastic Surgeons:Can The US Really Cut Health Care Spending? ... is one of the strongest sectors of the ailing ... health care spending is not probable. The author, who ...
Cached Medicine News:Health News:Gene plays dual role in breast cancers with poor prognosis 2Health News:Conference on cell therapy includes new session on stem cells for non-cardiac organ injury 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 2Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 3Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 4Health News:PR Newswire Provides Grant to Ronald McDonald House and Habitat for Humanity in Cleveland 5Health News:Substance abuse adds millions to Medicaid's total health care costs 2Health News:Substance abuse adds millions to Medicaid's total health care costs 3Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: